ScholarIQanswers from OpenAlex & ORCID
Jeffrey A. Engelman
ResearcherPublications, citations & collaboration network
Jeffrey A. Engelman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeffrey A. Engelman have?
ScholarIQindexed works
Jeffrey A. Engelman has 876 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeffrey A. Engelman have?
ScholarIQcitation count
Jeffrey A. Engelman has 86,315 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeffrey A. Engelman?
ScholarIQh-index
Jeffrey A. Engelman has an h-index of 132 in OpenAlex.
What is the i10-index of Jeffrey A. Engelman?
ScholarIQi10-index
Jeffrey A. Engelman has an i10-index of 227 in OpenAlex.
What is the ORCID of Jeffrey A. Engelman?
ScholarIQorcid
The ORCID for Jeffrey A. Engelman is on the source record.
What is the OpenAlex record for Jeffrey A. Engelman?
ScholarIQopenalex
The OpenAlex for Jeffrey A. Engelman is on the source record.
What are the most-cited papers on Jeffrey A. Engelman?
ScholarIQmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Subba R. Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer S. Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman, Ji Luo, Lewis C. Cantley
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn, Chris Greenman, Anahita Dastur, King Wai Lau, Patricia Greninger, I. Richard Thompson, Xi Luo, Jorge Soares, Qingsong Liu, Francesco Iorio, Didier Surdez, Li Chen, Randy Milano, Graham R. Bignell, Ah Ting Tam, Helen Davies, Jesse A. Stevenson, Syd Barthorpe, Stephen Lutz, Fiona Kogera, Karl Lawrence, Anne McLaren-Douglas, Xeni Mitropoulos, Tatiana Mironenko, Helen Thi, Laura Richardson, Wenjun Zhou, Frances Jewitt, Tinghu Zhang, Patrick O’Brien, Jessica L. Boisvert, Stacey Price, Wooyoung Hur, Wanjuan Yang, Xianming Deng, Adam P. Butler, Hwan Geun Choi, Jae Won Chang, José Baselga, Ivan Stamenkovic, Jeffrey A. Engelman, Sreenath V. Sharma, Olivier Delattre, Julio Sáez-Rodríguez, Nathanael S. Gray, Jeffrey Settleman, P. Andrew Futreal, Daniel A. Haber, Michael R. Stratton, Sridhar Ramaswamy, Ultan McDermott, Cyril H. Benes